Abstract 125P
Background
Bevacizumab biosimilar (Avegra®) became available for patients in Russia since 2015. Since introduction, no real-world data except clinical cases was available. We decided to assess the safety and effectiveness of Avegra® in patients treated in daily practice according to national treatment protocols. Depending on the geography the study was divided into Apollon-11, conducted in Moscow, and Soyuz-Apollon, conducted in 18 regions of Russia. The final analysis summarizes pooled results of all regions.
Methods
This multicentre prospective observational post-authorization study of bevacizumab biosimilar combined with chemotherapy in patients with metastatic colorectal cancer was conducted in 28 centres in Russia from December 2019 to January 2023. Patients with metastatic colorectal cancer (mCRC), treated with bevacizumab at a dose of 5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination with standard chemotherapy regimens as a first line of therapy were included. Primary safety endpoints were the incidence of adverse reactions (ARs) related to bevacizumab and the rate of treatment discontinuation due to ARs.
Results
438 patients with mCRC in 28 research centres of the Russian Federation were included in the study. Median age of patients was 62 (28–87) years, ECOG performance status of £1. Most of the tumors were left-sided (67.8%) and had at least one RAS/BRAF mutation (55.9%). After median follow-up of 7.3 months, adverse reactions occurred in 11%, of which 2.7% were grade ³3. Treatment was discontinued in 2.8% of patients due to adverse reactions. Objective response was achieved in 37.9% of patients (95% CI 31.4 - 41.6) with 2.8% of complete responses. Median progression-free survival was 9.4 months (95% CI 8.1 - 10.7). Median overall survival was not reached.
Conclusions
Our findings are consistent with previously known bevacizumab safety and efficacy profile. Numerically low incidence of ARs is most likely due to reduced reporting of adverse events in real-world clinical practice settings.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
BIOCAD.
Funding
BIOCAD.
Disclosure
A. Tryakin, M. Fedyanin, F.V. Moiseenko: Financial Interests, Personal, Coordinating PI: BIOCAD. M. Mariam, O. Mironov, D. Stroyakovskiy, N. Sokolov, S. Orlova, E. Mantsyrev, A.V. Sultanbaev, A. Teterich, K. Babina, D. Yukalchuk, S. Borzyanitsa, A. Isyangulova, A. Saidullaeva, I. Chernova, E. Bobrova, N. Fadeeva: Financial Interests, Personal, Local PI: BIOCAD.
Resources from the same session
551P - Real-world incidence and outcomes of immune-related adverse events in NSCLC patients
Presenter: Andrea Knox
Session: Poster Display
Resources:
Abstract
552P - TROPION-Lung05: Datopotamab deruxtecan (Dato-DXd) in Asian patients (pts) with previously treated non-small cell lung cancer (NSCLC) with actionable genomic alterations (AGAs)
Presenter: Yasushi Goto
Session: Poster Display
Resources:
Abstract
553P - Preceding plasma EGFR vs upfront tissue NGS for advanced NSCLC in the Chinese population: A single centre experience in Hong Kong
Presenter: Janet Du
Session: Poster Display
Resources:
Abstract
554P - Comparison of the analytical performance of endobronchial ultrasound-guided transbronchial needle aspiration and other sampling methods for the Oncomine Dx target test: An observational study
Presenter: Kazuhito Miyazaki
Session: Poster Display
Resources:
Abstract
555P - Quality of life in patients with stage IV non-small cell lung cancer and the influence of druggable mutations over time: A prospective, territory-wide study in Hong Kong
Presenter: Jason C S Ho
Session: Poster Display
Resources:
Abstract
556P - Results from the phase I study on efficacy and safety of iruplinalkib (WX-0593) for anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) patients who received prior second-generation ALK tyrosine kinase inhibitors (TKIs)
Presenter: xuezhi Hao
Session: Poster Display
Resources:
Abstract
557P - Longitudinal plasma proteomic profiling of EML4-ALK positive lung cancer receiving ALK-TKIs therapy
Presenter: Shasha Wang
Session: Poster Display
Resources:
Abstract
558P - Treatment duration and adherence of brigatinib as second-line treatment after crizotinib for ALK+ NSCLC in South Korea
Presenter: Jeong Eun Lee
Session: Poster Display
Resources:
Abstract
559P - Comprehensive survey of AACR GENIE database revealed a wide range of TMB distribution among all three classes (I, II, III) of BRAF mutated NSCLC
Presenter: Zhaohui Arter
Session: Poster Display
Resources:
Abstract
560P - Triple-targeted therapy of dabrafenib, trametinib and osimertinib for the treatment of acquired BRAF V600E mutation after progression on EGFR-TKIs in advanced EGFR-mutant NSCLC
Presenter: Chengdi Weng
Session: Poster Display
Resources:
Abstract